Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies announces that it has executed with Zambon, the Italian chemical and pharmaceutical Company (“Zambon”), a strategic collaboration and licence agreement for Newron’s lead compound safinamide. In aggregate, the total Zambon investment in Newron will be €20m as defined below, also covering the completion of safinamide’s clinical development and the preparation of the application for marketing approval in Europe and the US.
